JPWO2019243159A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019243159A5 JPWO2019243159A5 JP2020568439A JP2020568439A JPWO2019243159A5 JP WO2019243159 A5 JPWO2019243159 A5 JP WO2019243159A5 JP 2020568439 A JP2020568439 A JP 2020568439A JP 2020568439 A JP2020568439 A JP 2020568439A JP WO2019243159 A5 JPWO2019243159 A5 JP WO2019243159A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- salt
- solvate
- indicated
- variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims 64
- 239000011780 sodium chloride Substances 0.000 claims 64
- 239000012453 solvate Substances 0.000 claims 62
- 102000004965 antibodies Human genes 0.000 claims 57
- 108090001123 antibodies Proteins 0.000 claims 57
- 239000000427 antigen Substances 0.000 claims 33
- 102000038129 antigens Human genes 0.000 claims 33
- 108091007172 antigens Proteins 0.000 claims 33
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 28
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 claims 13
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims 13
- 101700073818 CDR1 Proteins 0.000 claims 12
- 102100002977 CDR1 Human genes 0.000 claims 12
- 108060001277 CDR2 Proteins 0.000 claims 12
- 102100008744 CDR2 Human genes 0.000 claims 12
- 101700027814 CDR3 Proteins 0.000 claims 12
- AYEKOFBPNLCAJY-UHFFFAOYSA-O thiamine pyrophosphate Chemical compound CC1=C(CCOP(O)(=O)OP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N AYEKOFBPNLCAJY-UHFFFAOYSA-O 0.000 claims 12
- 235000008170 thiamine pyrophosphate Nutrition 0.000 claims 12
- 101710025651 CXCR5 Proteins 0.000 claims 6
- 102100002072 CXCR5 Human genes 0.000 claims 6
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 238000002619 cancer immunotherapy Methods 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 229940079593 drugs Drugs 0.000 claims 3
- 230000002491 angiogenic Effects 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 230000003463 hyperproliferative Effects 0.000 claims 2
- 230000001225 therapeutic Effects 0.000 claims 2
- 230000003000 nontoxic Effects 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18178299 | 2018-06-18 | ||
| EP18178299.6 | 2018-06-18 | ||
| PCT/EP2019/065517 WO2019243159A1 (de) | 2018-06-18 | 2019-06-13 | Gegen cxcr5 gerichtete binder-wirkstoff-konjugate mit enzymatisch spaltbaren linkern und verbessertem wirkungsprofil |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021527640A JP2021527640A (ja) | 2021-10-14 |
| JPWO2019243159A5 true JPWO2019243159A5 (ko) | 2022-06-21 |
Family
ID=62705502
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020568439A Pending JP2021527640A (ja) | 2018-06-18 | 2019-06-13 | 酵素的に切断可能なリンカーおよび改善された活性プロファイルを有する、ｃｘｃｒ５に対して向けられるバインダー／活性薬剤複合体 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210275686A1 (ko) |
| EP (1) | EP3806908A1 (ko) |
| JP (1) | JP2021527640A (ko) |
| KR (1) | KR20210033470A (ko) |
| CN (1) | CN112601553A (ko) |
| AU (1) | AU2019289506A1 (ko) |
| BR (1) | BR112020025718A2 (ko) |
| CA (1) | CA3103327A1 (ko) |
| EA (1) | EA202190059A1 (ko) |
| IL (1) | IL279400A (ko) |
| MX (1) | MX2020013832A (ko) |
| SG (1) | SG11202012608VA (ko) |
| WO (1) | WO2019243159A1 (ko) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20180452A1 (es) | 2015-06-23 | 2018-03-05 | Bayer Pharma AG | Conjugados homogeneos especificos de sitio con inhibidores de ksp |
| RU2018136778A (ru) | 2016-03-24 | 2020-04-24 | Байер Фарма Акциенгезельшафт | Пролекарства цитотоксических лекарственных средств, содержащие ферментативно расщепляемые группы |
| US11001636B2 (en) | 2016-06-15 | 2021-05-11 | Bayer Pharma Aktiengesellschaft | Specific antibody-drug-conjugates (ADCs) with KSP inhibitors and anti-CD123-antibodies |
| EP3558388A1 (de) | 2016-12-21 | 2019-10-30 | Bayer Pharma Aktiengesellschaft | Binder-wirkstoff-konjugate (adcs) mit enzymatisch spaltbaren gruppen |
| WO2018114798A1 (de) | 2016-12-21 | 2018-06-28 | Bayer Aktiengesellschaft | Prodrugs von cytotoxischen wirkstoffen mit enzymatisch spaltbaren gruppen |
| JP7030811B2 (ja) | 2016-12-21 | 2022-03-07 | バイエル・ファルマ・アクティエンゲゼルシャフト | Ｋｓｐ阻害剤を有する特異的抗体－薬物コンジュゲート（ａｄｃ） |
| TW202216771A (zh) | 2020-06-26 | 2022-05-01 | 德商拜耳廠股份有限公司 | 用於治療應用之ccr8抗體 |
| MX2023008628A (es) | 2021-01-22 | 2023-09-22 | Bayer Ag | Anticuerpos lrrc15 y conjugados de los mismos. |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US4714681A (en) | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| US4925648A (en) | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
| US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
| GB8905592D0 (en) | 1989-03-10 | 1989-04-19 | Gkn Technology Ltd | Automatic length adjuster |
| WO1991000360A1 (en) | 1989-06-29 | 1991-01-10 | Medarex, Inc. | Bispecific reagents for aids therapy |
| US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
| DE69130709T3 (de) | 1990-10-05 | 2005-12-22 | Celldex Therapeutics, Inc. | Gezielte immunostimulierung mit bispezifischen stoffen |
| WO1992008802A1 (en) | 1990-10-29 | 1992-05-29 | Cetus Oncology Corporation | Bispecific antibodies, method of production, and uses thereof |
| ATE144624T1 (de) | 1991-04-26 | 1996-11-15 | Surface Active Ltd | Neue antikörper und verfahren zu ihrer verwendung |
| WO1993017715A1 (en) | 1992-03-05 | 1993-09-16 | Board Of Regents, The University Of Texas System | Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells |
| JP4436457B2 (ja) | 1995-08-18 | 2010-03-24 | モルフォシス アイピー ゲーエムベーハー | 蛋白質／（ポリ）ペプチドライブラリー |
| US20040249127A1 (en) | 2001-07-12 | 2004-12-09 | Olga Bandman | Intracellular signaling molecules |
| SG114505A1 (en) | 2001-10-17 | 2005-09-28 | First Cube Pte Ltd | System and method for facilitating delivery and return service |
| CA2467916A1 (en) | 2001-12-06 | 2003-06-19 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| WO2004100873A2 (en) | 2003-05-07 | 2004-11-25 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| ES2579836T3 (es) | 2003-11-06 | 2016-08-17 | Seattle Genetics, Inc. | Compuestos de monometilvalina capaces de conjugación con ligandos |
| US7939539B2 (en) | 2003-11-25 | 2011-05-10 | Novartis Vaccines And Diagnostics, Inc. | Quinazolinone compounds as anticancer agents |
| US7662581B1 (en) | 2003-12-18 | 2010-02-16 | Novartis Vaccines And Diagnostics, Inc. | Eg5 co-crystals |
| MXPA06014909A (es) | 2004-06-18 | 2007-02-28 | Chiron Corp | Derivados de n-(1-(1-bencil -4-fenil-1h -imidazol -2-il)-2, 2-dimetilpropil) benzamida y compuestos relacionados como inhibidores de proteina de huso de cinesina (ksp) para el tratamiento del cancer. |
| US7449486B2 (en) | 2004-10-19 | 2008-11-11 | Array Biopharma Inc. | Mitotic kinesin inhibitors and methods of use thereof |
| WO2006060737A2 (en) | 2004-12-03 | 2006-06-08 | Takeda San Diego, Inc. | Mitotic kinesin inhibitors |
| TW200800951A (en) | 2005-08-09 | 2008-01-01 | Novartis Ag | Substituted imidazole compounds as KSP inhibitors |
| DOP2006000277A (es) | 2005-12-12 | 2007-08-31 | Bayer Pharmaceuticals Corp | Anticuerpos anti mn y métodos para su utilización |
| EA200900924A1 (ru) | 2007-01-05 | 2009-12-30 | Новартис Аг | Циклизованные производные как ингибиторы eg-5 |
| BRPI0815983A2 (pt) * | 2007-08-29 | 2018-05-22 | Sanofi Aventis | anticorpos anti-cxcr5 humanizados, derivados dos mesmos e seus usos |
| KR101972303B1 (ko) | 2011-06-10 | 2019-04-25 | 메르사나 테라퓨틱스, 인코포레이티드 | 단백질-중합체-약물 접합체 |
| WO2014151030A1 (en) | 2013-03-15 | 2014-09-25 | Novartis Ag | Cell proliferation inhibitors and conjugates thereof |
| BR112015027388A2 (pt) | 2013-05-02 | 2017-08-29 | Ares Trading Sa | Anticorpo monoclonal ou porção do mesmo que se liga a cxcr5, seu método de produção e seu uso, polinucleotídeos, vetores de expressão, célula hospedeira, e composição farmacêutica |
| ES2815098T3 (es) | 2013-12-23 | 2021-03-29 | Bayer Pharma AG | Conjugados de ligadores (ADCs) con inhibidores de KSP |
| CN107635586B (zh) | 2014-12-15 | 2021-09-24 | 拜耳医药股份有限公司 | Ksp抑制剂与无糖基化抗-tweakr抗体的抗体-药物缀合物(adc) |
| CA2990076A1 (en) * | 2015-06-22 | 2016-12-29 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups |
| RU2018136778A (ru) * | 2016-03-24 | 2020-04-24 | Байер Фарма Акциенгезельшафт | Пролекарства цитотоксических лекарственных средств, содержащие ферментативно расщепляемые группы |
| EP3558388A1 (de) * | 2016-12-21 | 2019-10-30 | Bayer Pharma Aktiengesellschaft | Binder-wirkstoff-konjugate (adcs) mit enzymatisch spaltbaren gruppen |
-
2019
- 2019-06-13 BR BR112020025718-4A patent/BR112020025718A2/pt unknown
- 2019-06-13 WO PCT/EP2019/065517 patent/WO2019243159A1/de unknown
- 2019-06-13 EA EA202190059A patent/EA202190059A1/ru unknown
- 2019-06-13 SG SG11202012608VA patent/SG11202012608VA/en unknown
- 2019-06-13 AU AU2019289506A patent/AU2019289506A1/en active Pending
- 2019-06-13 US US17/253,086 patent/US20210275686A1/en active Pending
- 2019-06-13 JP JP2020568439A patent/JP2021527640A/ja active Pending
- 2019-06-13 KR KR1020217001448A patent/KR20210033470A/ko unknown
- 2019-06-13 MX MX2020013832A patent/MX2020013832A/es unknown
- 2019-06-13 CA CA3103327A patent/CA3103327A1/en active Pending
- 2019-06-13 CN CN201980054004.9A patent/CN112601553A/zh active Pending
- 2019-06-13 EP EP19729312.9A patent/EP3806908A1/de active Pending
-
2020
- 2020-12-13 IL IL279400A patent/IL279400A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240279327A1 (en) | Dual specific antibodies | |
| RU2636043C2 (ru) | Анти-vegf/dll4-иммуноглобулины с двойными вариабельными доменами и их применения | |
| JP2019146572A5 (ko) | ||
| US8889130B2 (en) | Treatment of osteoarthritis and pain | |
| JP2022191301A5 (ko) | ||
| JP2020509027A5 (ko) | ||
| JP2019532056A5 (ko) | ||
| JPWO2021183359A5 (ko) | ||
| JP2017534253A5 (ko) | ||
| RU2018119165A (ru) | Антитело против лиганда 1 запрограммированной гибели клеток (pd-l1), его антигенсвязывающий фрагмент и их медицинское применение | |
| US11225515B2 (en) | Macrophage stimulating protein receptor (or RON—recepteur d'Origine Nantais) antibodies and uses thereof | |
| RU2019122802A (ru) | Конъюганты связующего и активного вещества (adc), имеющие ферментативно расщепляемые группы | |
| JP2009532336A5 (ko) | ||
| JP2003525061A5 (ko) | ||
| JP2016531915A5 (ko) | ||
| JP2016538318A5 (ko) | ||
| JP2012522513A5 (ko) | ||
| JP2014524902A5 (ko) | ||
| JP2017522861A5 (ko) | ||
| JP2012532851A5 (ko) | ||
| RU2012103212A (ru) | Tlr3 связывающие агенты | |
| JP2020500834A5 (ko) | ||
| JP2015533781A5 (ko) | ||
| CN110022903B (zh) | Met抗体药物缀合物 | |
| RU2019139093A (ru) | Фармацевтическая композиция на основе антитела к pd-l1 и ее применение |